{"id":"https://openalex.org/W7220868912","doi":"https://doi.org/10.7759/cureus.117596","title":"Practical Pathological Assessment of Residual Cancer Burden (RCB) After Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Invasive Breast Carcinoma: A Case Report","display_name":"Practical Pathological Assessment of Residual Cancer Burden (RCB) After Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Invasive Breast Carcinoma: A Case Report","publication_year":2026,"publication_date":"2026-10-07","ids":{"openalex":"https://openalex.org/W7220868912","doi":"https://doi.org/10.7759/cureus.117596","pmid":"https://pubmed.ncbi.nlm.nih.gov/42997876","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13743059"},"language":"en","primary_location":{"id":"doi:10.7759/cureus.117596","doi":"https://doi.org/10.7759/cureus.117596","is_oa":true,"landing_page_url":"https://doi.org/10.7759/cureus.117596","pdf_url":"https://www.cureus.com/articles/535244-practical-pathological-assessment-of-residual-cancer-burden-rcb-after-neoadjuvant-therapy-in-human-epidermal-growth-factor-receptor-2-her2-positive-invasive-breast-carcinoma-a-case-report.pdf","source":{"id":"https://openalex.org/S2738950867","display_name":"Cureus","issn_l":"2168-8184","issn":["2168-8184"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310316779","host_organization_name":"Cureus, Inc.","host_organization_lineage":["https://openalex.org/P4310316779"],"host_organization_lineage_names":["Cureus, Inc."],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cureus","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.cureus.com/articles/535244-practical-pathological-assessment-of-residual-cancer-burden-rcb-after-neoadjuvant-therapy-in-human-epidermal-growth-factor-receptor-2-her2-positive-invasive-breast-carcinoma-a-case-report.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5125739279","display_name":"Gunvanti Rathod","orcid":"https://orcid.org/0000-0002-1045-8707","observed_orcids":["https://orcid.org/0000-0002-1045-8707"]},"institutions":[{"id":"https://openalex.org/I4405252828","display_name":"All India Institute of Medical Sciences Bibinagar","ror":"https://ror.org/000trq935","country_code":"IN","type":"education","lineage":["https://openalex.org/I4405252828"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Gunvanti Rathod","raw_affiliation_strings":["Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND","institution_ids":["https://openalex.org/I4405252828"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067565949","display_name":"Chandramouli Ramalingam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405252828","display_name":"All India Institute of Medical Sciences Bibinagar","ror":"https://ror.org/000trq935","country_code":"IN","type":"education","lineage":["https://openalex.org/I4405252828"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Chandramouli R","raw_affiliation_strings":["Department of Radiation Oncology, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND","institution_ids":["https://openalex.org/I4405252828"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086466778","display_name":"Immanuel Pradeep","orcid":"https://orcid.org/0000-0002-9652-0179","observed_orcids":["https://orcid.org/0000-0002-9652-0179"]},"institutions":[{"id":"https://openalex.org/I4405252828","display_name":"All India Institute of Medical Sciences Bibinagar","ror":"https://ror.org/000trq935","country_code":"IN","type":"education","lineage":["https://openalex.org/I4405252828"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Immanuel Pradeep","raw_affiliation_strings":["Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND","institution_ids":["https://openalex.org/I4405252828"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030216715","display_name":"Ajay Kumar Kondeti","orcid":"https://orcid.org/0000-0003-0661-6095","observed_orcids":["https://orcid.org/0000-0003-0661-6095"]},"institutions":[{"id":"https://openalex.org/I4405252828","display_name":"All India Institute of Medical Sciences Bibinagar","ror":"https://ror.org/000trq935","country_code":"IN","type":"education","lineage":["https://openalex.org/I4405252828"]}],"countries":["IN"],"is_corresponding":true,"raw_author_name":"Ajay Kumar Kondeti","raw_affiliation_strings":["Department of Radiation Oncology, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND","institution_ids":["https://openalex.org/I4405252828"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5030216715"],"corresponding_institution_ids":["https://openalex.org/I4405252828"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.68565724,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"18","issue":"10","first_page":"e117596","last_page":"e117596"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.88919997215271,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.88919997215271,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.07259999960660934,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11134","display_name":"Breast Lesions and Carcinomas","score":0.02539999969303608,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/residual-cancer-burden","display_name":"residual cancer burden","score":0.9399999976158142},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.906000018119812},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.902999997138977},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.8209999799728394},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.7609999775886536},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.7760000228881836},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9929999709129333},{"id":"https://openalex.org/keywords/trastuzumab-emtansine","display_name":"trastuzumab emtansine","score":0.7670000195503235},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.7260000109672546},{"id":"https://openalex.org/keywords/axillary-lymph-node-involvement","display_name":"axillary lymph node involvement","score":0.5920000076293945}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9837999939918518},{"id":"https://openalex.org/C2778292576","wikidata":"https://www.wikidata.org/wiki/Q6991934","display_name":"Neoadjuvant therapy","level":4,"score":0.7157999873161316},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7031000256538391},{"id":"https://openalex.org/C207886595","wikidata":"https://www.wikidata.org/wiki/Q1456138","display_name":"Pathological","level":2,"score":0.6801999807357788},{"id":"https://openalex.org/C2908728163","wikidata":"https://www.wikidata.org/wiki/Q415271","display_name":"Human Epidermal Growth Factor Receptor 2","level":4,"score":0.6758000254631042},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6176000237464905},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5738999843597412},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.4494999945163727},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4438999891281128},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.3345000147819519},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.3192000091075897},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3172999918460846},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.2987000048160553}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.7759/cureus.117596","doi":"https://doi.org/10.7759/cureus.117596","is_oa":true,"landing_page_url":"https://doi.org/10.7759/cureus.117596","pdf_url":"https://www.cureus.com/articles/535244-practical-pathological-assessment-of-residual-cancer-burden-rcb-after-neoadjuvant-therapy-in-human-epidermal-growth-factor-receptor-2-her2-positive-invasive-breast-carcinoma-a-case-report.pdf","source":{"id":"https://openalex.org/S2738950867","display_name":"Cureus","issn_l":"2168-8184","issn":["2168-8184"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310316779","host_organization_name":"Cureus, Inc.","host_organization_lineage":["https://openalex.org/P4310316779"],"host_organization_lineage_names":["Cureus, Inc."],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cureus","raw_type":"journal-article"},{"id":"pmid:42997876","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42997876","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cureus","raw_type":"Case Reports"}],"best_oa_location":{"id":"doi:10.7759/cureus.117596","doi":"https://doi.org/10.7759/cureus.117596","is_oa":true,"landing_page_url":"https://doi.org/10.7759/cureus.117596","pdf_url":"https://www.cureus.com/articles/535244-practical-pathological-assessment-of-residual-cancer-burden-rcb-after-neoadjuvant-therapy-in-human-epidermal-growth-factor-receptor-2-her2-positive-invasive-breast-carcinoma-a-case-report.pdf","source":{"id":"https://openalex.org/S2738950867","display_name":"Cureus","issn_l":"2168-8184","issn":["2168-8184"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310316779","host_organization_name":"Cureus, Inc.","host_organization_lineage":["https://openalex.org/P4310316779"],"host_organization_lineage_names":["Cureus, Inc."],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cureus","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7220868912.pdf","grobid_xml":"https://content.openalex.org/works/W7220868912.grobid-xml"},"referenced_works_count":13,"referenced_works":["https://openalex.org/W1891489226","https://openalex.org/W2023944710","https://openalex.org/W2050761481","https://openalex.org/W2096145980","https://openalex.org/W2144183889","https://openalex.org/W2329721570","https://openalex.org/W2800158081","https://openalex.org/W2902218997","https://openalex.org/W3122861570","https://openalex.org/W3199819343","https://openalex.org/W4361004330","https://openalex.org/W4390498811","https://openalex.org/W4413856338"],"related_works":["https://openalex.org/W2019038454","https://openalex.org/W4401360056","https://openalex.org/W2944108263","https://openalex.org/W2137495773","https://openalex.org/W4414060651","https://openalex.org/W2329012206","https://openalex.org/W2250057990","https://openalex.org/W3164145867","https://openalex.org/W3133246336","https://openalex.org/W2268258973"],"abstract_inverted_index":{"Neoadjuvant":[0],"therapy":[1],"is":[2,31,36,178],"routinely":[3],"used":[4],"in":[5,22,47,73,146,153,181],"human":[6],"epidermal":[7],"growth":[8],"factor":[9],"receptor":[10,88],"2":[11],"(HER2)-positive":[12],"breast":[13,91],"carcinoma":[14,92],"and":[15,38,76,102,149,169,200,208,235,259],"permits":[16],"the":[17,23,42,63,66,189],"assessment":[18,61,225,258],"of":[19,44,65,97,167,191,229,250],"treatment":[20],"response":[21,29],"surgical":[24],"specimen.":[25],"Although":[26],"pathological":[27],"complete":[28],"(pCR)":[30],"an":[32],"important":[33],"endpoint,":[34],"it":[35,187],"binary":[37],"does":[39],"not":[40,179],"quantify":[41],"extent":[43],"residual":[45,70,113,132,206,211,251],"disease":[46,237,252],"patients":[48],"with":[49,84,140,164,216],"non-pCR.":[50],"The":[51,158],"Residual":[52],"Cancer":[53],"Burden":[54],"(RCB)":[55],"index":[56,160],"provides":[57],"a":[58,81,117,130,209,217,247],"standardized":[59],"quantitative":[60],"incorporating":[62],"dimensions":[64],"treated":[67,220],"tumor":[68,119,152,221],"bed,":[69],"cancer":[71,143],"cellularity,":[72,144],"situ":[74,147],"component,":[75,148],"nodal":[77,233],"involvement.":[78],"We":[79],"report":[80],"48-year-old":[82],"woman":[83],"HER2-positive,":[85],"estrogen":[86],"receptor/progesterone":[87],"(ER/PR)-negative":[89],"invasive":[90,133,212],"who":[93],"received":[94],"six":[95],"cycles":[96],"neoadjuvant":[98,196],"TCH":[99],"(docetaxel,":[100],"carboplatin,":[101],"trastuzumab)":[103],"followed":[104],"by":[105,245],"modified":[106],"radical":[107],"mastectomy.":[108],"Gross":[109],"examination":[110],"showed":[111],"no":[112,150],"mass":[114],"but":[115,186],"identified":[116],"fibrotic":[118],"bed":[120],"measuring":[121,135],"7":[122],"\u00d7":[123,125,137],"5":[124,126],"cm.":[127],"Microscopy":[128],"demonstrated":[129],"single":[131],"focus":[134,213],"0.4":[136,138],"cm":[139],"10%":[141],"overall":[142],"1%":[145],"metastatic":[151],"13":[154],"axillary":[155],"lymph":[156],"nodes.":[157],"RCB":[159,182,224,242],"was":[161,174],"1.891":[162],"(RCB-II),":[163],"final":[165],"staging":[166],"ypT1aN0,":[168],"adjuvant":[170],"ado-trastuzumab":[171],"emtansine":[172],"(T-DM1)":[173],"initiated.":[175],"This":[176],"case":[177],"novel":[180],"or":[183],"HER2-directed":[184],"therapy,":[185],"demonstrates":[188],"importance":[190],"meticulous":[192],"tumor-bed":[193],"evaluation":[194],"after":[195],"chemotherapy.":[197],"Treatment-related":[198],"fibrosis":[199],"inflammatory":[201],"change":[202],"may":[203,214],"obscure":[204],"scattered":[205],"carcinoma,":[207],"small":[210],"coexist":[215],"substantially":[218],"larger":[219],"bed.":[222],"Accurate":[223],"therefore":[226],"requires":[227],"correlation":[228],"gross":[230],"findings,":[231],"microscopy,":[232],"evaluation,":[234],"pre-treatment":[236],"location.":[238],"In":[239],"this":[240],"setting,":[241],"complements":[243],"pCR":[244],"providing":[246],"reproducible":[248],"description":[249],"that":[253],"can":[254],"support":[255],"multidisciplinary":[256],"risk":[257],"management.":[260]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-10-08T00:00:00"}